ImmuPharma (LON:IMM) Trading 25.3% Higher - Here's Why

Key Points

• ImmuPharma plc's stock price surged by 25.3%, reaching a high of GBX 19.35 ($0.26) during trading, compared to a close of GBX 13.98 ($0.19) the previous day.
• Trading volume increased significantly to 65,638,188 shares, marking a 677% rise from the average session volume of 8,446,959 shares.
• The company reported a quarterly earnings loss of GBX (0.38) per share, with analysts projecting a significant negative earnings per share of -339.0000022 for the current year.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price traded up 25.3% during mid-day trading on Tuesday . The stock traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). 65,638,188 shares traded hands during trading, an increase of 677% from the average session volume of 8,446,959 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Performance

The company has a 50-day moving average of GBX 3.43 and a 200-day moving average of GBX 3.01. The stock has a market capitalization of £77.24 million, a price-to-earnings ratio of -1,736.74 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.